ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,615.35
      0.55%
      US Tech 100
      19,804.00
      0.64%
      Dow Jones
      40,000.90
      0.62%
      Brent Oil
      84.57
      0.00%
      Bitcoin
      58,664.18
      1.34%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Lexicon Pharmaceuticals Inc (LXRX)

      7. Lexicon Pharmaceuticals Inc (LXRX) News

      LXRX

      Lexicon Pharmaceuticals (LXRX)

      Lexicon Pharmaceuticals Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:LXRX
      DateTimeSourceHeadlineSymbolCompany
      11/15/20175:16PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/14/20176:56PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/08/20174:41PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/08/20178:22AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/08/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals Reports Third Quarter 2017 Financial Results And Provides A Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/03/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals To Host Third Quarter 2017 Financial Results Conference Call And Webcast On November 8, 2017NASDAQ:LXRXLexicon Pharmaceuticals Inc
      11/02/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals To Present At Upcoming Investor ConferencesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/27/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals Initiates Patient Dosing In A Phase 1 Study Of LX9211NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/19/201712:33PMPR Newswire (US)European Commission Approves XERMELO® (Telotristat Ethyl) For The Treatment Of Carcinoid Syndrome Diarrhea In Combination Wi...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/18/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals To Present At The 2017 Cantor Fitzgerald Global Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/18/20176:41AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/18/20176:37AMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/15/20175:23PMEdgar (US Regulatory)Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/13/20174:31AMPR Newswire (US)New England Journal Of Medicine Publishes Data From Phase 3 inTandem3 Study Of Sotagliflozin In Patients With Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/08/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 inTandem1 And inTande...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/07/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals Announces Four Data Presentations At The European Society Of Medical Oncology 2017 CongressNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/07/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals To Present At The Bank Of America Merrill Lynch 2017 Global Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      09/05/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals to Present New Clinical Data at the European Association for the Study of Diabetes 53rd Annual Meetin...NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/15/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals Reports Additional Positive Data From Pivotal Phase 3 inTandem2 Study Of SotagliflozinNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/14/201712:00PMEdgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/03/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals To Present At 2017 Wedbush PacGrow Healthcare ConferenceNASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20174:16PMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20174:09PMEdgar (US Regulatory)Amended Quarterly Report (10-q/a)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20177:19AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      08/01/20177:00AMPR Newswire (US)Lexicon Pharmaceuticals Reports Second Quarter 2017 Financial Results And Provides A Business UpdateNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/31/20176:01PMPR Newswire (US)Lexicon Pharmaceuticals Announces Opt-In Decision For U.S. Co-Promotion Of Sotagliflozin With Sanofi In Type 1 DiabetesNASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/24/20179:00AMPR Newswire (US)Lexicon Pharmaceuticals To Host Second Quarter 2017 Financial Results Conference Call And Webcast On August 1, 2017NASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/21/20177:27AMPR Newswire (US)Lexicon Collaborator Ipsen Receives Positive CHMP Opinion For Xermelo® (Telotristat Ethyl)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      07/07/20178:46AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LXRXLexicon Pharmaceuticals Inc
      06/19/20177:00AMPR Newswire (US)NCCN Guidelines For Neuroendocrine Tumors Include XERMELO In Combination With Somatostatin Analog Therapy As A Recommended Tr...NASDAQ:LXRXLexicon Pharmaceuticals Inc
       Showing the most relevant articles for your search:NASDAQ:LXRX